Evogene (EVGN) FCF Payout Ratio (2020 - 2026)

Evogene (EVGN) posted FCF Payout Ratio of 2.88 for Q1 2026, down 94.68% sequentially from 1.48 in Q1 2025, and down 94.68% YoY from 54.23 in Q1 2025.

Evogene (EVGN) FCF Payout Ratio (2020 - 2026) Analysis & Trends

Evogene has reported FCF Payout Ratio for 4 years, with the latest figure at 2.88 in Q1 2026.

Quarterly FCF Payout Ratio fell 94.68% year-over-year to 2.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.28 (down 30.19% YoY) and the FY2025 annual result came in at 0.97, changed N/A from the prior year.
FCF Payout Ratio eased to 2.88 in Q1 2026 per EVGN's latest filing, from 1.48 in the prior quarter.
Over five years, FCF Payout Ratio peaked at 1.48 in Q1 2025 and troughed at 2.88 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.17
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.07
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	-2.88

Download Data